Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 29, 2015 8:31 AM ET

Healthcare Equipment and Supplies

Company Overview of Fenwal Inc.

Company Overview

Fenwal Inc. develops products for transfusion medicine and cell therapies. The company offers various products and services, which focuses on apheresis collections, therapeutic procedures, and manual collection processes. It offers component collection and processing systems including Amicus, a system that collects mononuclear cells, therapeutic plasma, and RBCs; Alyx, a mobile and multi-component collection, processing, and leuko-filtration system; Autopheresis-C and Aurora, an automated system that streamlines plasma collection and produces virtually cell-free plasma for operators and donors; and InterSol, a platelet additive solution. The company also provides blood collection units with ...

Three Corporate Drive

Lake Zurich, IL 60047

United States

Founded in 1949





Key Executives for Fenwal Inc.

Chief Financial Officer and Senior Vice President
Chief Executive Officer of Fresenius Kabi Region North America and President of Fresenius Kabi Region North America
President of Medical Devices for Fresenius Kabi North America
Chief Technology Officer and Senior Vice President
Age: 55
Chief Information Officer and Senior Vice President
Compensation as of Fiscal Year 2015.

Fenwal Inc. Key Developments

Fenwal Receives FDA Clearance to Include New Clinical Data in the Product Label of its Platelet Additive Solution, InterSol

Fenwal announced it has received FDA clearance to include new clinical data in the product label of its platelet additive solution, InterSol(TM) (PAS 3). A multi-center, non-randomized, open-label retrospective medical chart review study involving about 14,000 transfusions looked at adverse events related to platelet transfusion with and without additive solution. Platelet transfusions using Fenwal InterSol led to a 0.55% adverse event reaction rate, while transfusions using only plasma platelets led to a 1.37% adverse event reaction rate. Clinical experience has suggested that allergic transfusion reactions may be reduced by replacing a portion of the total plasma volume with platelet additive solution. Fenwal InterSol solution replaces approximately 65% of the plasma used for platelet storage, on platelets collected on the Fenwal Amicus(R) separator. The results of this study are consistent with these previous findings. No adverse safety trends were identified after a review of all the adverse events by the Independent Clinical Events Committee. Platelet transfusions using Fenwal InterSol resulted in a 0.29% allergic reaction rate, while transfusions using only plasma platelets resulted in a 0.82% allergic reaction rate. Febrile Non-Hemolytic Transfusions reaction events were associated with 0.17% of platelet transfusions with Fenwal's InterSol and 0.50% of transfusions with plasma platelets.

Similar Private Companies By Industry

Company Name Region
Blue Belt Technologies, Inc. United States
Ischemia Technologies, Inc. United States
PointCare Technologies, Inc. United States
DJO Finance Corporation United States
ARKRAY USA, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Fenwal Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at